AbbVie在2025年的Q4比预期收入高,提高了2026年的指导意见,投资者的兴趣也增加了。 AbbVie beat earnings expectations in Q4 2025, raised 2026 guidance, and saw increased investor interest.

AbbVie Inc.报告2025年第四季度的收入比预期的要强,EPS收入为271美元,收入为166.2亿美元,逐年增长10%。 AbbVie Inc. reported stronger-than-expected fourth-quarter 2025 earnings, with $2.71 in EPS and $16.62 billion in revenue, up 10% year-over-year. 该公司将其2026年全年EPS指导意见提高到14.37至14.57美元,其第一季度预测为2.97至3.01美元。 The company raised its 2026 full-year EPS guidance to $14.37–$14.57 and its first-quarter forecast to $2.97–$3.01. 机构投资者,包括NEOS投资管理和卡达诺风险管理,增加了他们的股份. Institutional investors, including NEOS Investment Management and Cardano Risk Management, increased their stakes. 截至2026年2月初,AbbVie的股票开放量为231.57美元,市场上限为409.28亿美元,P/E比率为98.12美元,“Moderate Buy”分析员评级为251.00美元。 As of early February 2026, AbbVie’s stock opened at $231.57 with a $409.28 billion market cap, a P/E ratio of 98.12, and a “Moderate Buy” analyst rating with a $251.00 target. 该公司总部设在伊利诺伊州北芝加哥,其重点是免疫学、肿瘤学、神经科学和妇女健康方面的专科药物。 The company, based in North Chicago, Illinois, focuses on specialty medicines in immunology, oncology, neuroscience, and women’s health.